OVH Groupe completes the acquisition of Gladia, expert in voice AI

Roubaix, July 31, 2026 OVH Groupe (Euronext Paris: OVH), a sovereign, global player and European leader in Cloud and AI, announces the completion of the acquisition of Gladia, the expert in AI speech-to-text (STT), announced on June 11, 2026. The transaction was carried out by way of a contribution in kind of shares, in consideration for which newly issued OVH Groupe shares were allotted (the “Transaction”).

Bleichroeder Acquisition Corp. III Announces the Separate Trading of its Class A Ordinary Shares and Warrants, Commencing August 3, 2026

NEW YORK, NY, July 31, 2026 (GLOBE NEWSWIRE) — Bleichroeder Acquisition Corp. III (Nasdaq: BCCQU) (the “Company”) announced today that, commencing August 3, 2026, the holders of the units issued in the Company’s initial public offering (the “Units”), each consisting of one Class A ordinary share of the Company, par value $0.0001 per share (the “Class A Ordinary Shares”), and one-fourth of one redeemable warrant of the Company (each, a “Warrant”), with each whole Warrant entitling the holder thereof to purchase one Class A Ordinary Share for $11.50 per share, may elect to separately trade the Class A Ordinary Shares and the Warrants included in the Units. No fractional Warrants will be issued upon separation of the Units and only whole Warrants will trade. The Class A Ordinary Shares and the Warrants will trade on the Nasdaq Global Market under the symbols “BCCQ” and “BCCQW,” respectively. Units not separated will continue to trade on the Nasdaq Global Market under the symbol “BCCQU.”

This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities of the Company, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Bleichroeder Acquisition Corp. III

Moleculin Announces Pricing of $9.3 Million Public Offering 

HOUSTON, July 31, 2026 (GLOBE NEWSWIRE) — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), today announced the pricing of a best-efforts public offering of an aggregate of 12,376,667 shares of common stock (or pre-funded warrants in lieu thereof), and warrants (the “Common Warrants”) to purchase up to 37,130,001 shares of common stock at a combined public offering price of $0.75 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants. The Common Warrants will be immediately exercisable at an exercise price of $0.75 per share and will expire five years following the initial exercise date. The offering is expected to close on or about August 3, 2026, subject to satisfaction of customary closing conditions.

Solitics Unveils Next-Generation Agentic AI for Retail Banking Customer Engagement

RAMAT GAN, Israel, July 31, 2026 (GLOBE NEWSWIRE) — Solitics, a SaaS industry leader in adaptive engagement and smart marketing automation, announces the release of Saai, a suite of intelligent tools designed to dramatically reduce manual work with full integration guaranteed within 45 days. An agentic AI built specifically for marketing and product teams in this industry, it promises to accelerate campaign execution and unlock deeper insights across the CRM workflow within retail banking. 

Limagrain and Qi Biodesign sign worldwide licensing agreement for genome editing technologies to accelerate the development of next-generation crop varieties

Limagrain and leading genome editing player Beijing Qi Biodesign Biotechnology Co., Ltd. (“Qi Biodesign”) today announced a global licensing agreement granting Limagrain access to a portfolio of genome editing technologies for field and vegetable crops.  This collaboration agreement marks a new milestone in Limagrain’s strategy to expand into next-generation breeding technologies and reinforce its leadership in crop innovation.

Luda Technology Group Limited has signed a sales blanket agreement worth about RMB1.6 billion to supply pipeline fittings for the Yulong Island Refining and Chemical Integration Project (Phase one).

Hong Kong, July 31, 2026 (GLOBE NEWSWIRE) — Luda Technology Group Limited (the “Company” or “Luda Technology”) (NYSE: LUD), a manufacturer and trader of stainless steel and carbon steel flanges and fittings products, announced today that the Company has signed a sales blanket agreement worth about RMB1.6 billion with Shandong Yulong Petrochemical Company, Limited to supply pipeline fittings for the Yulong Island Refining and Chemical Integration Project (Phase one).

EAST WEST AVE ACQUISITION CORP. ANNOUNCES PRICING OF $100 MILLION INITIAL PUBLIC OFFERING

NEW YORK, July 31, 2026 (GLOBE NEWSWIRE) — East West Ave Acquisition Corp. (NASDAQ: EWAVU) (the “Company”) announced the pricing of its initial public offering (the “IPO”) of 10,000,000 units at $10.00 per unit. The units are expected to trade on the Nasdaq Global Market (“Nasdaq”) under “EWAVU” beginning July 31, 2026. Each unit consists of one share of common stock, and one right to receive one-fourth of one share of common stock upon consummation of an initial business combination. Upon separate trading, the common stock and rights are expected to be listed on Nasdaq under “EWAV” and “EWAVR” respectively.

NOMAD Power Solutions Announces Options Trading Begins on Cboe Options Exchange

Boca Raton, Fla., July 31, 2026 (GLOBE NEWSWIRE) — NOMAD Power Solutions, Inc. (“NOMAD” or the “Company”) (Nasdaq: NMAD), a leader in transportable, utility-grade battery energy storage systems through its wholly owned subsidiary NOMAD Transportable Power Systems, today announced that the Company’s common stock is now available for options trading on the Cboe Options Exchange under the symbol “NMAD.”

SciSparc: Subsidiary NeuroThera Labs’ Quantum Platform Demonstrates Complete End-to-End Hybrid Quantum-Classical Workflow for Clinical Data Analytics

TEL AVIV, Israel, July 31, 2026 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (“Company” or “SciSparc”), today announced that NeuroThera Labs Inc. (TSXV: NTLX) (“NeuroThera”), a clinical-stage pharmaceutical company focused on developing novel treatments for central nervous system disorders, announced another technological milestone achieved by NeuroThera’s quantum sampling workflow platform for clinical trials data analytics (the “Platform”).